Which suppositories are used for prostatitis?

Which suppositories are suitable for prostatitis at all?

Different suppositories are used in the treatment of prostatitis – especially the common non-bacterial form (CPPS) – which mainly differ in their mechanism of action and therapeutic goal. Since bacterial infection is not the primary issue in CPPS, local therapies primarily aim to reduce pain, modulate inflammatory processes, and stabilize tissue. Rectal suppositories offer the advantage of making active ingredients directly available in the prostate area, allowing targeted effects with minimal systemic exposure.

Basically, several categories can be distinguished. Classic anti-inflammatory suppositories contain active ingredients such as NSAIDs or local corticosteroids and are mainly used for short-term pain relief. However, their effect is often limited because they do not address the complex causes of CPPS. Herbal or phytotherapeutic suppositories rely on antioxidant and anti-inflammatory effects and are particularly suitable for longer-term use with good tolerability, although the evidence is variable. Modern therapeutic approaches, on the other hand, follow a multimodal approach: suppositories with cannabidiol (CBD) and hyaluronic acid – such as CANNEFF® SUP – combine pain-relieving, anti-inflammatory, and tissue-protective effects, thus targeting several pathophysiological mechanisms simultaneously. Initial clinical data show a relevant improvement in pain and urinary symptoms with very good tolerability.

Which suppositories are suitable for prostatitis largely depends on the symptoms and cause. While classic preparations mainly provide symptomatic relief, modern local therapy approaches offer a more comprehensive method that better fits the multifactorial nature of CPPS.

When are suppositories useful for prostatitis – and when are they not?

Suppositories are particularly useful for prostatitis when symptoms occur locally in the pelvic area and a targeted, well-tolerated therapy is desired. This applies especially to non-bacterial prostatitis (CPPS), where pain, pressure in the perineum, or functional complaints are predominant. Through rectal application, active ingredients can act directly near the prostate, achieving a high local concentration without burdening the entire body. Especially in chronic cases or in patients who poorly tolerate or respond inadequately to systemic medications, suppositories represent a useful supplement or alternative. They can also be used specifically within a multimodal therapy concept to locally influence pain, inflammation, and tissue irritation.

Suppositories are not useful as a sole therapy for clearly bacterial prostatitis, as antibiotic treatment is the primary approach here. They also reach their limits when complex systemic factors dominate, such as pronounced neurological pain processing disorders or severe psychosocial stress that require further therapy. In such cases, suppositories can be used as supportive treatment but do not replace comprehensive care.

Suppositories are an effective local therapy option, especially for chronic, non-bacterial forms. However, their use should always depend on the individual symptoms and – particularly in complex cases – be part of a comprehensive treatment plan.

What role do rectal suppositories play in abacterial prostatitis and CPPS?

Rectal suppositories play an increasingly important role in the treatment of abacterial prostatitis (CPPS), as they enable targeted local therapy in the area of the prostate and surrounding tissue. Unlike systemic medications that act throughout the body, suppositories act directly at the site of symptoms. This is particularly relevant in CPPS, where local pain processes, neurogenic inflammation, and functional disorders in the pelvic area play a central role.

Through rectal application, active ingredients can be released in immediate proximity to the prostate, achieving a high local concentration. At the same time, systemic burden is reduced, which improves tolerability and facilitates long-term use. This is a decisive advantage, especially in chronic cases that require continuous therapy. Rectal suppositories can also address several pathophysiological mechanisms simultaneously, such as pain processing, inflammatory reactions, and tissue irritation.

In modern therapy, rectal suppositories are therefore mainly used as part of a multimodal approach. They complement systemic therapies such as medications or physiotherapy and help improve symptom control. In particular, innovative local preparations with combined mechanisms of action offer an expanded therapeutic approach, as they not only act symptomatically but also regulate the underlying processes.

Rectal suppositories are an important component of modern therapy for CPPS, as they enable effective, locally targeted treatment. They are especially suitable for chronic cases and can specifically support the effectiveness of multimodal therapy concepts.

Can anti-inflammatory suppositories relieve symptoms of prostatitis?

Anti-inflammatory suppositories can contribute to short-term relief of pain and irritation symptoms in prostatitis – especially in the abacterial form (CPPS) – but their effect is usually limited. Their use mainly aims to reduce local inflammatory processes and thereby decrease acute symptoms such as pressure sensation, burning, or pain in the pelvic area. Especially during phases of increased symptom intensity, they can therefore represent a useful supportive measure.

However, their effectiveness in CPPS is limited because the condition is usually not primarily caused by a classic inflammation. Instead, complex mechanisms such as central sensitization, neurogenic inflammation, and muscular dysfunction are predominant. Anti-inflammatory suppositories only partially address these processes, which is why the symptom relief achieved is often not permanent. For this reason, they are used in practice more as part of a combined therapy rather than as a sole treatment.

Anti-inflammatory suppositories can temporarily relieve symptoms of prostatitis but are usually not sufficient on their own. Their greatest benefit lies in supportive use within a multimodal therapy concept, especially for short-term symptom control.

What advantages do suppositories have over tablets in prostatitis?

Suppositories offer several decisive advantages over tablets in the treatment of prostatitis – especially in the abacterial form (CPPS) – because they act locally and targeted, while tablets are distributed systemically throughout the body. Through rectal application, the active ingredients reach the immediate vicinity of the prostate, allowing for a higher local concentration at the site of action. This enables a more effective influence on pain, inflammation, and tissue irritation in the pelvic area.

Another advantage lies in the reduced systemic burden. While tablets are absorbed through the gastrointestinal tract and metabolized by the liver, suppositories partially bypass this route. This can reduce typical side effects – such as those in the gastrointestinal area or cardiovascular strain. This is especially relevant for patients who are sensitive to medications or require long-term therapy.

Furthermore, suppositories are especially suitable for chronic courses because they can be used continuously and over longer periods. They can also be specifically integrated into multimodal therapy concepts to support local processes while other measures act systemically in parallel. Especially in CPPS, where multiple mechanisms are involved simultaneously, this combination represents an important therapeutic advantage.

Suppositories offer clear advantages in prostatitis when a targeted, locally effective, and well-tolerated therapy is desired. They are particularly a useful addition or alternative to tablets in chronic cases because they act directly at the site of the symptoms while reducing systemic side effects.

Which active ingredients are used in suppositories for prostatitis?

In the treatment of prostatitis – especially the abacterial form (CPPS) – many active ingredients are used in suppositories that pursue different therapeutic goals. While classic preparations mainly aim for short-term pain relief, modern and plant-based combinations show a broader approach by also combining anti-inflammatory, neuroregulatory, and tissue-protective effects.

Basically, the active ingredients used can be divided into three main groups: classic pharmacological substances, plant-based active ingredients, and modern multimodal active ingredient combinations. Classic agents like NSAIDs or corticosteroids mainly have anti-inflammatory and pain-relieving effects but often fall short because they do not fully address the complex causes of CPPS. Additionally, locally acting anesthetics are used to block pain directly in the tissue for a short time.

Plant-based active ingredients primarily target the regulation of tissue, inflammation, and local irritation processes. These include pumpkin seed extract, frankincense (Boswellia), Centella asiatica, calendula, and tea tree oil. These substances have antioxidant, anti-inflammatory, and tissue-regenerating effects but usually act more as supportive agents.

Modern therapeutic approaches combine several mechanisms of action in a targeted way. Particularly relevant here is the combination of cannabidiol (CBD) and hyaluronic acid, as used in CANNEFF® SUP suppositories. While CBD influences pain processing and neurogenic inflammation via the endocannabinoid system, hyaluronic acid provides protection and regeneration of the mucosa. This multimodal approach is especially important in chronic cases.

How effective are CBD and hyaluronic acid suppositories like CANNEFF® SUP for CPPS?

CBD and hyaluronic acid suppositories like CANNEFF® SUP show clinically relevant improvement of symptoms in chronic abacterial prostatitis or CPPS according to current study data. In a pilot study, 16 men with CP/CPPS were treated intrarectally for 30 days. The NIH-CPSI total score significantly decreased by 7.2 points (p = 0.001). The pain subscore also improved significantly by 3.75 points (p = 0.005). Additionally, the IPSS improved from a median of 13.5 to 10 (p = 0.002), with the study summary noting that urinary symptoms were especially reduced. Overall, 81.3% of patients showed clinical improvement, while no adverse events were reported. The IIEF-5 increased slightly, but this effect was not statistically significant (p = 0.09).

The study also directly compares these results with established therapies. The observed symptom reduction of a similar magnitude is comparable to quercetin with about 6 points, alpha-blockers with about 5–6 points, or celecoxib with about 8 points, although according to the study slide, the effect of celecoxib may diminish after the end of therapy. The authors therefore rate CANNEFF® SUP as a clinically significant, locally effective, and non-systemic therapy option that can be comparable to systemic treatments. At the same time, it is clearly pointed out that the results come from a single-arm open pilot study and therefore need to be confirmed by larger controlled studies. A controlled clinical study is currently underway.

Comparison: PROSTUROL®, CANNEFF® SUP, and classic suppositories for prostatitis

Classic suppositories for prostatitis primarily act symptomatically by temporarily reducing pain and inflammatory processes. They typically contain active ingredients such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or local anesthetics and are mainly used for acute complaints. Their mode of action is rather monofactorial, as they mainly address individual symptoms and less the complex causes of the disease. Accordingly, their effect is usually limited to short-term relief, while systemic side effects – especially with prolonged use – are possible.

PROSTUROL® follows a plant-based regulatory and at the same time tissue-protective approach. The active ingredients such as pumpkin seed extract, boswellia, centella, calendula, tea tree oil, and vitamin E primarily have anti-inflammatory effects and support local tissue regulation. This approach is complemented by hyaluronic acid, which contributes to the stabilization and regeneration of the mucous membrane. The pain-relieving effect occurs rather indirectly through the improvement of the local tissue environment. PROSTUROL® is therefore particularly suitable for chronic, mild to moderate courses and is characterized by very good tolerability as well as good suitability for long-term use.

CANNEFF® SUP suppositories also combine hyaluronic acid with an additional mode of action through cannabidiol (CBD). While hyaluronic acid supports tissue protection and regeneration, CBD has anti-inflammatory effects and influences pain processing via the endocannabinoid system. This results in a multimodal therapeutic approach that simultaneously addresses several key mechanisms of CPPS, including pain, inflammation, and tissue irritation. Clinical data show a significant reduction in pain and urinary symptoms with very good tolerability. CANNEFF® is therefore especially suitable for chronic courses and can be well integrated into a long-term, multimodal therapy concept.

Overall, the three approaches differ less in individual ingredients and more in their therapeutic depth: while classic suppositories mainly provide short-term symptomatic relief, PROSTUROL® and CANNEFF® SUP offer a multifactorial approach – with the difference that CANNEFF® additionally specifically targets pain regulation via the endocannabinoid system.

How are suppositories correctly used for prostatitis?

Suppositories are used rectally for prostatitis – especially for CPPS – to enable targeted local action in the prostate area. Correct application is crucial for effectiveness, as it influences how well the active ingredients distribute in the tissue and how long they remain at the site of action.

The application is usually done once daily, preferably in the evening. The timing is deliberately chosen because the body is at rest and the suppository has enough time to dissolve and release the active ingredients locally. Hands should be washed thoroughly before use. The suppository is then carefully removed from the packaging and inserted tip first into the rectum. A relaxed position – such as lying on the side with legs slightly bent – makes insertion much easier.

It is important to insert the suppository deeply enough so that it does not slip out again. After application, it is ideally recommended to lie still for a few minutes to support the absorption of the active ingredients. Additionally, it is advisable to empty the bowel before use, as this improves absorption and prevents the suppository from being expelled prematurely.

The duration of use depends on the individual symptom profile but is often about 30 days in studies and clinical practice, especially for chronic courses like CPPS. If necessary, the use can be extended or repeated as part of a multimodal therapy concept.

Which suppositories are best for prostatitis?

There is no universally "best" suppository for prostatitis, as the optimal choice strongly depends on the individual symptom profile and the underlying form of the disease. What matters more is which mechanism of action best fits the dominant symptoms. While acute pain requires short-term symptomatic relief, chronic courses like CPPS require a targeted, long-term strategy.

For acute symptoms, classic anti-inflammatory suppositories can be useful as they quickly reduce pain. However, they are not a sustainable solution for chronic courses. Herbal preparations like PROSTUROL® are particularly suitable for patients with mild to moderate symptoms who prefer a well-tolerated, regulatory therapy and especially focus on tissue protection and anti-inflammatory effects.

In chronic abacterial prostatitis (CPPS), however, it has been shown that multimodal approaches deliver the best results. Here, suppositories with combined mechanisms of action – especially those that affect inflammation, pain processing, and tissue – offer clear advantages. Preparations like CANNEFF® SUP with CBD and hyaluronic acid address several key mechanisms simultaneously and thus most closely correspond to the modern understanding of the disease.

Sources

Zhang, Z. C., & Peng, J. (2013). Zhonghua nan ke xue = National journal of andrology, 19(7), 579–582. https://pubmed.ncbi.nlm.nih.gov/24386866/

Nickel, J. C., Alexander, R. B., Anderson, R., Berger, R., Comiter, C. V., Datta, N. S., Fowler, J. E., Krieger, J. N., Landis, J. R., Litwin, M. S., McNaughton-Collins, M., O'Leary, M. P., Pontari, M. A., Schaeffer, A. J., Shoskes, D. A., White, P., Kusek, J., Nyberg, L., & Chronic Prostatitis Collaborative Research Network Study Groups (2008). Category III chronic prostatitis/chronic pelvic pain syndrome: insights from the National Institutes of Health Chronic Prostatitis Collaborative Research Network studies. Current urology reports, 9(4), 320–327. https://doi.org/10.1007/s11934-008-0055-7

AU Guidelines on Chronic Pelvic Pain D. Engeler (Chair), A.P. Baranowski, B. Berghmans, A.M. Cottrell, J. Dütschler, I. Flink, I.M. Grzybowska, B. Parsons, K. Petersen, R.A. Pinto, V. Tidman, B. Vyawahare Guidelines Associates: P. Abreu-Mendes, R. Husein, A. Nic an Riogh Patient Advocates: J. Birch, M.L. van Poelgeest https://uroweb.org/guidelines/chronic-pelvic-pain/summary-of-changes/2025